Taysha adds Kathy Reape and Laura Sepp-Lorenzino to Board of Directors

EFFECTIVE DATE:

Chartwell Partners is honored to have been selected to partner with Taysha Gene Therapies on appointing new Board members: Kathy Reape, M.D., former Chief Medical Officer of Spark Therapeutics, and Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer of Intellia Therapeutics. Both women bring broad pharmaceutical industry experience and tremendous gene therapy expertise to Taysha, from leading preclinical stage programs through clinical development and commercialization. They will be important contributors as the Company advances its extensive portfolio into the clinic and works towards its mission to eradicate monogenic CNS disease. For more information on these appointments, please visit https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-adds-industry-leading-gene-therapy.